Pulmonary arterial hypertension: basis of sex differences in incidence and treatment response.
Br J Pharmacol
; 171(3): 567-79, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-23802760
ABSTRACT
Pulmonary arterial hypertension (PAH) is a complex disease characterized by elevated pulmonary arterial pressure, pulmonary vascular remodelling and occlusive pulmonary vascular lesions, leading to right heart failure. Evidence from recent epidemiological studies suggests the influence of gender on the development of PAH with an approximate female to male ratio of 41, depending on the underlying disease pathology. Overall, the therapeutic strategy for PAH remains suboptimal with poor survival rates observed in both genders. Endogenous sex hormones, in particular 17ß oestradiol and its metabolites, have been implicated in the development of the disease; however, the influence of sex hormones on the underlying pathobiology remains controversial. Further understanding of the influence of sex hormones on the normal and diseased pulmonary circulation will be critical to our understanding the pathology of PAH and future therapeutic strategies. In this review, we will discuss the influence of sex hormones on the development of PAH and address recent controversies.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fármacos Cardiovasculares
/
Circulação Pulmonar
/
Medicina Baseada em Evidências
/
Hipertensão Pulmonar
/
Pulmão
/
Modelos Biológicos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article